|
|
Founded: |
June 30, 2006 |
|
Management: |
| Kurt B. Osther, MD |
Founder/Chairman/CSO |
| Jeffrey Zweiben |
CEO |
| John Larsen |
Founder/Director | |
|
Scientific Advisors: |
|
|
Focus: |
Genetic engineering of humanized recombinant proteins in the area of hemostasis and wound healing. |
|
Products: |
The initial development of Human Recombinant Thrombin, Human Recombinant Fibrinogen and Human Recombinant Collagen type III has been successful. All above products will enter into pre-clinical trials during spring and summer of 2007. |
|
Patent Portfolio: |
- CFM patent application purchased from Interface Biotech.
- 3 patents pending securing the individual as well as the combination products and their IP derived from Recombinant Human Thrombin, Recombinant Human Fibrinogen, Recombinant Human Collagen type III, HumaSealant, HumaSealant-C
|
|
Cooperation: |
HumaGene has entered into a formal collaborative research, development and exploitation agreement with one of Scandinavia’s major bio tech companies. |
|
Our Logo: |
 |
|
|
 |
|
|
|
|
|
|
|
|
